Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan OKs Coverage for Susmed Insomnia App, Shionogi ADHD Therapy App
Japan’s Central Social Insurance Medical Council (Chuikyo) on May 13 approved insurance coverage for digital therapeutics developed by Susmed for insomnia and by Shionogi for ADHD, with reimbursements set to begin on June 1. The reimbursement price for Susmed’s insomnia…
To read the full story
Related Article
- Shionogi ADHD App to Go Out-of-Pocket after 2 Treatment Cycles
September 17, 2026
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
- Shionogi Releases Japan’s First Therapy App for Pediatric ADHD
June 8, 2026
- Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
- Japan Approves Shionogi’s Therapy App for Pediatric ADHD
February 19, 2025
REGULATORY
- US Narrows Scope of Medicare MFN Model, Exempts Orphan-Only Drugs
October 2, 2026
- Japan to Draw Up Growth Strategy Action Plan by Year-End
October 2, 2026
- Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
October 1, 2026
- Repatha Optimal Use Guidelines to Be Simplified
October 1, 2026
- Label Revisions Ordered for Checkpoint Inhibitors over Gastritis, Esophagitis
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…